Core Viewpoint - The pharmaceutical sector is experiencing a rebound, with significant stock price increases for several companies following regulatory support for innovative drug clinical trial approvals [1] Group 1: Stock Performance - Several pharmaceutical stocks have seen notable gains, including: - Hutchison China MediTech (00013) up 11.04% to HKD 27.96 - Innovent Biologics (09969) up 10.76% to HKD 18.63 - Zai Lab (09688) up 7.84% to HKD 26.14 - Lepu Biopharma-B (02157) up 7.3% to HKD 8.53 - CanSino Biologics (09926) up 6.5% to HKD 136 [1] Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) has proposed to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [1] - This initiative supports key national R&D projects and encourages global early-stage synchronized development and international multi-center clinical trials [1] Group 3: Market Sentiment and Challenges - There are concerns regarding potential restrictions on Chinese innovative drugs in the U.S. market, but many pharmaceutical companies believe these rumors will not significantly impact the prospects for Chinese drugs abroad [1] - HSBC notes that the short-term emotional impact of these rumors may be greater than the actual damage, as prohibiting patent transactions is technically challenging [1] - Global pharmaceutical companies are facing a "patent cliff" risk and are in need of high-quality Chinese assets to strengthen their product pipelines, leading to lobbying against such administrative orders [1]

Core Viewpoint - Pharmaceutical stocks experienced a rebound today, with significant gains observed in several companies following regulatory news from the National Medical Products Administration (NMPA) regarding the optimization of clinical trial review and approval processes for innovative drugs [1] Group 1: Stock Performance - Hutchison China MediTech (00013) rose by 11.04%, trading at HKD 27.96 [1] - Innovent Biologics (09969) increased by 10.76%, trading at HKD 18.63 [1] - Zai Lab (09688) saw a rise of 7.84%, trading at HKD 26.14 [1] - Lepu Biopharma-B (02157) gained 7.3%, trading at HKD 8.53 [1] - CanSino Biologics (09926) increased by 6.5%, trading at HKD 136 [1] Group 2: Regulatory Developments - The NMPA announced a plan to further optimize the review and approval process for clinical trials of innovative drugs, aiming to complete reviews within 30 working days for eligible applications [1] - This initiative supports key national R&D projects and encourages global early-stage synchronized development and international multi-center clinical trials [1] Group 3: Market Sentiment and Risks - Recent negative rumors regarding potential restrictions on Chinese innovative drugs entering the U.S. market have been noted, but several pharmaceutical companies believe these rumors do not currently impact the expectations for Chinese innovative drugs abroad [1] - HSBC indicated that the short-term emotional impact of these rumors may be greater than the actual damage, as prohibiting patent transactions is technically challenging [1] - Global pharmaceutical companies are facing a "patent cliff" risk and are in need of high-quality Chinese assets to strengthen their product pipelines, leading to lobbying against such administrative orders [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to share R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to discuss its latest R&D advancements, which will be live-streamed [1] - Dr. Shi Ming, the Executive Vice President and Chief Medical Officer, will present the company's R&D strategy and vision, focusing on the antibody-drug conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] Group 2: Future Milestones - According to Guotou Securities, several upcoming milestones for the company are noteworthy, with ATTC platform candidates set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib in the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study to the National Medical Products Administration in the first half of 2026 [1] - The first ATTC candidate drug is anticipated to initiate clinical trials in China and globally around the end of 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to discuss its latest R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to share its R&D strategies and vision, including an overview of its Antibody-Drug Conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] - The company’s Executive Vice President and Chief Medical Officer, Dr. Shi Ming, will present during the event [1] Group 2: Clinical Development Milestones - Multiple upcoming milestones for the company are anticipated, with ATTC platform candidate drugs set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib by the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study in the first half of 2026 [1] - The first ATTC candidate drug is projected to initiate clinical trials in China and globally around the end of 2025 [1]

Core Viewpoint - After a significant drop, Hong Kong's innovative drug concept stocks rebounded across the board, indicating market resilience and potential recovery in the sector [1] Group 1: Market Performance - As of the report, Kangning Jereh Pharmaceutical-B surged over 14%, Hutchison China MediTech rose more than 6%, Zai Lab and Lepu Biopharma B increased over 5%, and Akeso-B climbed over 4% [1] Group 2: Industry Sentiment - Several pharmaceutical companies have acknowledged rumors regarding potential restrictions from the U.S. on innovative drugs from China, but they believe these rumors do not currently impact the expectations for Chinese innovative drugs entering international markets [1] Group 3: Future Outlook - Market analysts predict that leading biotech companies such as BeiGene and Innovent Biologics are expected to reach a profitability inflection point by 2025, with a strong growth trajectory anticipated thereafter [1] - With improvements in industrial capabilities and product line expansions, it is expected that more biotech firms will enter a profitability cycle in the future [1]

Core Viewpoint - Hutchison China MediTech Limited (00013.HK) announced a conference scheduled for October 31, 2025, in Shanghai, China, to share its latest research and development progress, which will be live-streamed online [1] Group 1 - The conference will feature Dr. Shi Mingbo, Executive Vice President, Head of R&D, and Chief Medical Officer, who will discuss the company's R&D strategy and vision [1] - The presentation will include an overview of the company's Antibody-Drug Conjugate (ADC) platform and highlight its first candidate drug, HMPL-A251 [1] - Updates on the later-stage R&D pipeline will also be shared during the event [1]

Core Insights - HUTCHMED will host a Research & Development update on October 31, 2025, in Shanghai and via webcast [1][2] Group 1: Event Details - The event will feature Dr. Michael Shi, who will discuss the company's R&D strategy, including the Antibody Targeted Therapy Conjugates platform and updates on late-stage pipeline development [2] - The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese, with a live English webcast at 8:00 p.m. HKT [3] - Both webcasts will be available live on the company website, with a replay accessible shortly after the event [4] Group 2: Company Overview - HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 會議通知：和黃醫藥將於2025年10月31日介紹最新研發進展 — 和黃醫藥將於10月31日（星期五）舉行線下和線上會議 — 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）今日宣佈將於2025年10月31日（星期五）在 中國上海舉辦會議分享最新研發進展，並將通過網絡同步直播。 活動期間，和黃醫藥執行副總裁、研發負責人兼首席醫學官石明博士將分享公司的研發策略和願景，包括概述公司 抗體靶向偶聯藥物（ATTC）平台並重點介紹其首個候選藥物HMPL-A251，以及後期研發管綫的最新進展。 線下會議將於中國香港時間下午3時至5時於上海舉行，會議語言為中文（普通話），並將於網絡同步直播。現場活 動僅限受邀人士參與。 此外，英文場次的網絡會議將於10月31日（星 ...

Major Events - Yunzhisheng (09678) is actively exploring new sustainable business models and project opportunities [1] - Junshi Biosciences (01877) achieved the primary endpoint in the Phase III clinical study of anti-IL-17A monoclonal antibody for moderate to severe plaque psoriasis [1] - Hutchison China MediTech (00013) will present the latest data on several self-developed compounds at the 2025 World Lung Cancer Congress and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology [1] - InnoCare Pharma-B (09606) reached the primary endpoint in the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients [1] - Heng Rui Medicine (01276) plans to license its Class 1 innovative drug HRS-1893 to Braveheart Bio to expand into overseas markets [1] Financial Data - Aoyuan Group (01813) reported a pre-sale amount of 611 million yuan in August, a year-on-year decrease of 13.9% [1] - GAC Group (02238) sold 135,700 vehicles in August, a year-on-year decline of 8.43% [1] - Zhongliang Holdings (02772) recorded a cumulative contract sales amount of approximately 8.29 billion yuan in the first eight months, a year-on-year decrease of 32.71% [1] - Xiehe New Energy (00182) reported a total equity power generation of 507.64 GWh in August, a year-on-year increase of 6.07% [1] - Zhengrong Real Estate (06158) had a cumulative contract sales amount of approximately 2.99 billion yuan in the first eight months, a year-on-year decrease of 30.8% [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) is set to present updated data on its self-developed compounds at two major conferences in September 2025, highlighting its ongoing research in lung cancer treatment [1] Group 1: Upcoming Conferences - The company will present at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain from September 6 to 9 [1] - The company will also present at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of Savolitinib (赛沃替尼) for non-small cell lung cancer will be disclosed at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]